


Rheumatology, Allergy and Immunology



Update on Beta-Lactam Allergy

Kimberly G. Blumenthal, MD, MSc

Co-Director, Rheumatology & Allergy Clinical Epidemiology Research Center Director of Research, Drug and Vaccine Allergy Center Division of Rheumatology, Allergy, and Immunology Massachusetts General Hospital Associate Professor of Medicine Harvard Medical School




EAC Annual Conference 2024



Learning Objectives

- Upon completion of this learning activity, participants should be able to describe the rationale for, and approaches to, beta-lactam allergy evaluation
- Upon completion of this learning activity, participants should be able to address barriers to widespread penicillin allergy de-labeling

Why Penicillin Allergy Labels Matter



Castells NEJM 2019

The Effect of Penicillin Allergy Testing on Future Health Care Utilization: A Matched Cohort Study



Eric Macy, MD, MS^a, and Yu-Hsiang Shu, MS, PhD^b San Diego and Pasadena, Calif

Beta-Lactam Alternatives	Evaluated (n=308)	Not Evaluated (n=1,251)	P-Value
Cotrimoxazole	21.1	23.7	0.36
Clindamycin	14.6	32.5	<0.001
Macrolide	31.5	41.8	0.001
Tetracycline	24.0	19.2	0.07
Quinolone	31.5	30.7	0.84
Vancomycin	4.5	6.6	0.22
Aminoglycoside	11.0	14.6	0.12

Macy J Allergy Clin Immunol Pract 2017


Future Antibiotic Utilization

Beta-Lactams	Evaluated (n=308)	Not Evaluated (n=1,251)	P-Value
Penicillin courses	45.0	2.5	<0.001
1 st generation cephalosporin courses	32.5	20.5	<0.001
3 rd /4 th /5 th generation cephalosporin courses	13.3	15.3	0.42
Carbapenems	1.0	0.2	0.10
Monobactam	0.3	1.0	0.33

Macy J Allergy Clin Immunol Pract 2017

Penicillin Allergy Testing Is Cost-Saving: An Economic Evaluation Study

Bernardo Sousa-Pinto, ^{1,2,3,0} Kimberly G. Blumenthal,⁴⁵ Eric Macy,⁶ Ana Margarida Pereira,^{1,2} Luís Filipe Azevedo,^{1,2} Luís Delgado,^{2,3} and João Almeida Fonseca^{1,2}



Sousa-Pinto Clin Infect Dis 2020

Support for Penicillin Allergy Assessments

Don't overuse non-beta lactam antibiotics in patients with a history of penicillin allergy, without an appropriate evaluation.

While about 10 percent of the population reports a history of penicillin allergy, studies show that 90 percent on more of these patients are not allergic to penicillins and are able to take these antibiotics safely. The main reason for this observation is that penicillin allergy is often misdiagnosed and when present wanes over time in most (but not all) individuals. Patients labeled penicillin-allergic are more likely to be treated with alternative antibiotics (such as vancomycin and quinolones), have higher medical costs, experience longer hospital stays, and are more likely to develop complications such as infections with vancomycin-resistant enterococcus (VRE) and Clostridium difficile.

Evaluation for specific IgE to penicillin can be carried out by skin testing. Ideally, penicillin skin testing should be performed with both major and minor determinants. The negative predictive value of penicillin skin testing for immediate reactions approaches 100 percent, whereas the positive predictive value is between 40 and 100 percent. The usefulness of in vitro tests for penicillin-specific IgE is limited by their uncertain predictive value. They are not suitable substitutes for penicillin skin testing.

By identifying the overwhelming majority of individuals who can safely receive penicillin and penicillin-like drugs, we can improve the appropriateness of antibiotic therapy and clinical care outcomes.

In patients with a history of β -lactam allergy, we suggest that ASPs promote allergy assessments and penicillin (PCN) skin testing when appropriate

Assessing penicillin allergy: About 15% of hospitalized patients report an allergy to penicillin^[68]. However, less than 1% of the US population has a serious penicillin allergy that would preclude treatment with a beta-lactam antibiotic^{(69]}. There are several effective approaches to properly assess penicillin allergies, including history and physical examination, challenge doses, and skin testing^(60, 71). Nurses may be able to play an important role in improving penicillin allergy assessments⁽²⁷⁾.





An initiative of the ABIM Foundation

American Academy of Allergy Asthma & Immunology



NICE Is it Real

Is it Really a Penicillin Allergy?



of Allergy, Asthma & Immunology



Consensus-Based Statement

Consensus-Based Statement	Strength of Recommendation	Certainty of Evidence
We recommend a proactive effort to de-label a penicillin allergy, if appropriate.	Strong	Moderate

Khan J Allergy Clin Immunol 2022

Penicillin Allergy Diagnostic Testing



Studies (N)	Sensitivity	Specificity
27	30.7% (18.9-45.9%)	96.8% (94.2-98.3%)

Sousa-Pinto J Allergy Clin Immunol 2021

Penicillin Skin Testing Reagents

Paagant	% positive skin test patterns among subjects
Reagent	With positive skin test result (N = 63)
PRE-PEN only	3
Minor determinant only	38
Amoxicillin only	6
PRE-PEN + MDM	8
PRE-PEN + amoxicillin	0
MDM + amoxicillin	21
PRE-PEN + MDM + amoxicillin	24






ABBREVIATIONS PRE-PEN, benzylpenicilloyl polylysine MDM, minor determinant

Solensky J Allergy Clin Immunol Pract 2019

Original Investigation

Assessing the Diagnostic Properties of a Graded Oral Provocation Challenge for the Diagnosis of Immediate and Nonimmediate Reactions to Amoxicillin in Children

Christopher Mill, MPH; Marie-Noël Primeau, MD; Elaine Medoff, MD; Christine Lejtenyi, MD; Andrew O'Keefe, MD; Elena Netchiporouk, MD; Alizee Dery, BSc; Moshe Ben-Shoshan, MD, MSc



Mill JAMA Pediatr 2016

Meta-Analysis: 28 Studies in Children

Public Author year Chambel 2010 Moral 2011 Mori 2015 Mill 2016 Vyles 2017 Ibářiez 2018 Arnold 2019 García Rodríguez 2019 Jaoui 2019	Country Portugal Spain Italy Canada Turkey USA Spain Canada	Positive reaction(s) 11 1 17 48 4 0 35	Iotal DPT (n) 114 50 177 818 119 100		ES (95% CI) 9.65 (5.47–16.46) 2.00 (0.35–10.50) 9.60 (6.08–14.84)	% Weight 3.28 2.03	Author Chambel Moral	Publication year 2010	Country Portugal	IHR from DPT	Total DPT (n) 114		ES (95% CI)	% Weight 2.91
Chambel 2010 Moral 2011 Morai 2015 Mill 2016 Vyles 2017 Ibáñez 2018 Labrosse 2018 Garcia Rodríguez 2019	Portugal Spain Italy Canada Turkey USA Spain Canada	11 1 17 48 4 0	114 50 177 818 119		9.65 (5.47–16.46) 2.00 (0.35–10.50)	3.28	Chambel	2010		0				
Moral 2011 Mori 2015 Mill 2016 Vyles 2017 Ibåñez 2018 Labrosse 2018 García Rodríguez 2019	Spain Italy Canada Turkey USA Spain Canada	1 17 48 4 0	50 177 818 119		2.00 (0.35-10.50)				Portugal		114		0.00 (0.00-3.26)	201
Mori 2015 Mill 2016 Vyles 2017 Ibáñez 2018 Labrosse 2018 Arnold 2019	Italy Canada Turkey USA Spain Canada	17 48 4 0	177 818 119			2.03	Moral							
Mill 2016 Vezir 2016 Vyles 2017 Ibáñez 2018 Labrosse 2018 Arnold 2019 García Rodríguez 2019	Canada Turkey USA Spain Canada	48 4 0	818 119		9.60 (6.08-14.84)			2011	Spain	0	50		0.00 (0.00-7.13)	1.58
Vezir 2016 Vyles 2017 Ibáñez 2018 Labrosse 2018 Arnold 2019 García Rodríguez 2019	Turkey USA Spain Canada	4 0	119			3.95	Mori	2015	Italy	3	177		1.69 (0.58-4.86)	3.81
Vyles 2017 Ibáñez 2018 Labrosse 2018 Arnold 2019 García Rodríguez 2019	USA Spain Canada	0			5.87 (4.45-7.69)	5.60	Mill	2016	Canada	17	818		2.08 (1.30-3.30)	6.76
lbáñez 2018 Labrosse 2018 Arnold 2019 Garcia Rodríguez 2019	Spain Canada		100	F	3.36 (1.31-8.32)	3.34	Vezir	2016	Turkey	1	119	- F	0.84 (0.15-4.61)	3.00
Labrosse 2018 Arnold 2019 Garcia Rodríguez 2019	Canada	35			0.00 (0.00-3.70)	3.07	Vyles	2017	USA	0	100	- E	0.00 (0.00-3.70)	2.67
Arnold 2019 García Rodríguez 2019			732		4.78 (3.46-6.58)	5.53	Ibáñez	2018	Spain	6	732		0.82 (0.38-1.78)	6.59
García Rodríguez 2019		6	130	1 F	4.62 (2.13-9.70)	3.48	Labrosse	2018	Canada	3	130		2.31 (0.79-6.57)	3.17
y	Australia	3	73	-	4.11 (1.41-11.40)	2.58	Arnold	2019	Australia	3	73	<u> </u>	4.11 (1.41-11.40)	2.13
2010	Spain	14	97		14.43 (8.80-22.78)	3.02	García Rodriguez	2019	Spain	2	97	-	2.06 (0.57-7.21)	2.61
	France	39	456		8.55 (6.32-11.48)	5.13	Jaoui	2019	France	1	456	- f	0.22 (0.04-1.23)	5.78
Pouessel 2019	France	13	91		14.29 (8.54-22.92)	2.92	Pouessel	2019	France	3	91	-	3.30 (1.13-9.25)	2.50
Allen 2020	Ireland	3	102	-	2.94 (1.01-8.29)	3.10	Allen	2020	Ireland	0	102		0.00 (0.00-3.63)	2.70
Krusenstjerna-Hafstrøm 2020	Denmark	4	144	-	2.78 (1.09-6.92)	3.64	Krusenstjerna-Hafstrøm	2020	Denmark	3	144		2.08 (0.71-5.95)	3.38
Kulhas Celik 2020	Turkey	10	365		2.74 (1.49-4.97)	4.90	Kulhas Celik	2020	Turkey	4	365		1.10 (0.43-2.78)	5.34
Labrosse 2020	Canada	5	158		3.16 (1.36-7.19)	3.78	Labrosse	2020	Canada	3	158		1.90 (0.65-5.43)	3.57
Petersen 2020	Denmark	22	305		7.21 (4.81-10.68)	4.69	Petersen	2020	Denmark	3	305		0.98 (0.34-2.85)	4.97
Wang 2020	USA	0	53	+	0.00 (0.00-6.76)	2.11	Wang	2020	USA	0	53	E-	0.00 (0.00-6.76)	1.66
Delli Colli 2021	Canada	5	75		6.67 (2.88-14.68)	2.62	Delli Colli	2021	Canada	2	75	_	2.67 (0.73-9.21)	2.17
Exius 2021	Canada	103	1,914		5.38 (4.46-6.48)	6.00	Exius	2021	Canada	42	1,914		2.19 (1.63-2.95)	7.71
Gateman 2021	Canada	3	41	-	7.32 (2.52-19.43)	1.77	Gateman	2021	Canada	3	41		7.32 (2.52-19.43)	1.35
Goh 2021	Singapore	3	80	-	3.75 (1.28-10.45)	2.72	Goh	2021	Singapore	0	80	-	0.00 (0.00-4.58)	2.28
Koosakulchai 2021	Thailand	5	54	-	9.26 (4.02-19.91)	2.14	Koosakulchai	2021	Thailand	0	54	···	0.00 (0.00-6.64)	1.69
Prieto 2021	Spain	24	194		12.37 (8.46-17.75)	4.09	Prieto	2021	Spain	0	194		0.00 (0.00-1.94)	4.00
Antoon 2022	USA	1	20		5.00 (0.89-23.61)	1.02	Antoon	2022	USA	1			5.00 (0.89-23.61)	0.72
Guðnadóttir 2022	Iceland		1,440		6.39 (5.24-7.77)	5.90	Guðnadóttir	2022	Iceland	9	1,440		0.63 (0.33-1.18)	7.45
Liccioli 2022	Italy	23	354		6.50 (4.37-9.56)	4.87	Liccioli	2022	Italy	2	354		0.56 (0.16-2.04)	5.28
Nauven 2022	LISA	0	70		0.00 (0.00-4.69)	2.69	Nouven	2022	LISA	0	78		0.00'0.00-4.69)	2 23
Overall (I^2 = 72.00%; P = .00)			٦	\$	5.23 (4.17-6.39)	100.00	Overall (I^2 = 55.10%; P	(00. =			_	Ī	0.80 (0.43-1.25)	100.00

Immediate Only

Immediate or nonimmediate

Srisuwatchari J Allergy Clin Immunol Pract 2023

CME Review


Who needs penicillin allergy testing?

Eric Macy, MD, MS*; David Vyles, DO, MS[†]

No. of Patients	Age Groups	Country	Immediate-Onset Positive	Delayed-Onset Positive
818	Children	Canada	17 (2.1%)	31 (3.5%)
328	Adults	United States	5 (1.5%)	0 (0%)
130	Children	Canada	3 (2.3%)	5 (3.8%)
155	Children and adults	United States	1 (0.6%)	3 (1.9%)
732	Children	Spain	6 (0.8%)	29 (4.0%)
617	Children (n=435) and adults (n=207)	Israel	9 (1.5%)	1 day: 24 (19.0%); 5 day: 30 (6.1%)
519	Children and adults	United States	1 (0.2%)	8 (1.6%)
3,299			42 (1.3%; 95%Cl 0.9-1.7%)	130 (3.9%; 95% Cl 3.3-4.7%)

Macy Ann Allergy Asthma Immunol 2018

Comparing Direct Challenge to Penicillin Skin Testing for the Outpatient Evaluation of Penicillin Allergy: A Randomized Controlled Trial



Mustafa J Allergy Clin Immunol Pract 2019

Defining "Low Risk": Prediction Models

	Anaphylatis	5CAR*	Index drug	Reaction in Reaction	e Required nent	tiapsed time since teaction	ecallof dri	Nutificients	Demographics
Chiriac et al.	+	-	+	+	?	+	?	+	-
Siew et al.	+	×	+	?	?	+	+	?	-
Stevenson et al.	+	×	×	?	?	+	?	?	-
Trubiano et al.	+	+	×	?	+	+	?	?	-
Moreno et al.	+	?	+	+	?	+	?	?	-
+ Associated [†] Excluded cephalosporins, index penicillin was not significant									

Not associated


? Unknown/Not considered


* SCAR is difficult to denote because studies differ in how it is used or grouped with other symptoms. Angioedema likewise difficult, but not excluded by any studies

× Excluded

Plager Curr Opin Allergy Clin Immunol 2021

PEN-FAST Risk Stratification





 Points

 0
 Very low risk of positive penicillin allergy test <1% (<1 in 100 patients reporting penicillin allergy)</td>

 1-2
 Low risk of positive penicillin allergy test 5% (1 in 20 patients)

 3
 Moderate risk of positive penicillin allergy test 20% (1 in 5 patients)

 4-5
 High risk of positive penicillin allergy test 50% (1 in 2 patients)


 a
 Includes unknown.

^b Forms of severe delayed reactions include potential SJS, TEN, DRESS and AGEP. Patients with a severe delayed rash with mucosal involvement should be considered to have a severe cutaneous adverse reaction. Acute interstitial nephritis, drug induced liver injury, serum sickness and isolated drug fever were excluded phenotypes from the derivation and validation cohorts.

	Direct Challenge	Skin Test	Risk Difference
Positive immune- mediated penicillin challenge	1 (0.5%)	1 (0.5%)	RD of 0.0084 pp (90% CI, −1.22 to 1.24 pp
Immune- mediated adverse events	9	10	RD, −0.45 pp; 95% Cl, −4.87 to 3.96 pp

Copaescu JAMA Intern Med 2023; Trubiano JAMA Intern Med 2020

Defining "Low Risk": MGH Allergy



Blumenthal J Allergy Clin Immunol Pract 2019


Consensus-Based Statement

Consensus-Based Statement	Strength of Recommendation	Certainty of Evidence
We recommend against testing inpatients with a history inconsistent with penicillin allergy (such as headache or family history of penicillin allergy), but a 1-step amoxicillin challenge may be offered to patients who are anxious or request additional reassurance to accept the removal of a penicillin allergy label.	Strong	Moderate
We suggest penicillin skin testing for patients with a history of anaphylaxis or a recent reaction suspected to be IgE-mediated.	Conditional	Low

Consensus-Based Statement


Consensus Based Statement	Strength of Recommendation	Certainty of Evidence
We recommend against penicillin skin testing prior to direct amoxicillin challenge in pediatric patients with a history of benign cutaneous reaction (such as maculopapular rashes and urticaria).	Strong	Moderate
We suggest that direct amoxicillin challenge be considered in adults with distant and benign cutaneous reaction histories (such as maculopapular rashes and urticaria).	Conditional	Low

Penicillin Allergy: Summary



Khan JACI 2022 (adapted by Deanna McDanel, PharmD)

Cross-Reactivity to Cephalosporins and Carbapenems in Penicillin-Allergic Patients: Two Systematic Reviews and Meta-Analyses



Cross-Reactivity to Cephalosporins and Carbapenems in Penicillin-Allergic Patients: Two Systematic Reviews and Meta-Analyses


Generation	Name	No. of studies	n/N	AR in % (95% Cl)
First	Cephalexin	8	97/693	14.00 (11.61-16.79)
	Cefadroxil	6	95/557	12.65 (5.85-25.26)
	Cephalothin	3	9/184	4.89 (2.56-9.13)
	Cefazolin	3	1/75	1.33 (0.19-8.86)
	Cefatrizine	2	1/56	1.79 (0.25-11.61)
	Cephaloridine	1	0/17	0.0 (0.0-19.5)
Second	Cefamandole	6	23/474	4.85 (3.25-7.20)
	Cefaclor	7	90/679	13.25 (10.91-16.02)
	Cefuroxime	14	16/984	0.96 (0.26-3.51)
	Cefprozil	1	3/39	7.69 (1.62-20.87)
Third	Cefpodoxime	1	1/71	1.4 (0.0-7.6)
	Ceftazidime	4	2/433	0.31 (0.02-4.72)
	Cefotaxime	4	5/436	1.15 (0.48-2.72)
	Cefixime	7	2/324	0.62 (0.15-2.43)
	Ceftriaxone	9	13/843	0.99 (0.25-3.87)
	Ceftibuten	3	0/153	0.0 (0.0-2.4)
Fourth	Cefepime	2	1/285	0.31 (0.01-10.32)

Picard JACI In Practice 2019

JAMA Surgery | Original Investigation

Assessment of the Frequency of Dual Allergy to Penicillins and Cefazolin

A Systematic Review and Meta-analysis




Sousa-Pinto JAMA Surg 2020

Use of Cephalosporins in Penicillin Allergy


Consensus-Based Statement	Strength of Recommendation	Certainty of Evidence	
We suggest that for patients with an unverified, non- anaphylactic, penicillin allergy, a cephalosporin can be administered without testing or additional precautions.	Conditional	Moderate	
We suggest that for patients with a history of anaphylaxis to penicillin, a non-cross-reactive cephalosporin can be administered without prior testing.	Conditional	Moderate	

Cephalosporins Administration in Penicillin Allergy




Khan J Allergy Clin Immunol 2022

Using Cephalexin in Penicillin Allergy




Khan JACI 2022 (adapted by Deanna McDanel, PharmD)

Using Cefazolin in Penicillin Allergy



Khan JACI 2022 (adapted by Deanna McDanel, PharmD)

Cefazolin in Penicillin Allergy Patients



Plager Ann Allergy Asthma Immunol 2020; Wolfson J Allergy Clin Immunol Pract 2020

Cephalosporin and Penicillin Administration in Cephalosporin Allergy

Consensus-Based Statement	Strength of Recommendation	Certainty of Evidence
We suggest that for patients with a history of non- anaphylactic cephalosporin allergy, direct challenges (without prior skin test) to cephalosporins with dissimilar side chains be performed to determine tolerance.	Conditional	Moderate
We suggest that for patients with a history of anaphylaxis to a cephalosporin, a negative cephalosporin skin test should be confirmed prior to administration of a parenteral cephalosporin with a non-identical R1 side chain.	Conditional	Low

Cephalosporin Administration in Cephalosporin Allergy

Cephalosporin Administration to Patient with Cephalosporin Hypersensitivity Nonanaphylactic History* Anaphylactic History* Structurally Structurally-similar dissimilar cephalosporin being cephalosporin given being given **Recommended Option:** Recommended Cephalosporin skin testing- guided Option: treatment¶ Drug Challenge[†]


Romano J Allergy Clin Immunol 2015

Penicillin Administration in Cephalosporin Allergy

Consensus-Based Statement	Strength of Recommendation	Certainty of Evidence
We suggest against penicillin skin testing in patients with a non-anaphylactic history to cephalosporins prior to administration of penicillin therapy.	Conditional	Low
We suggest that in patients with a history of anaphylaxis to cephalosporins, penicillin skin testing and drug challenge should be performed prior to administration of penicillin therapy.	Conditional	Low

Penicillin Administration in Cephalosporin Allergy

Penicillin Administration to Patient with Cephalosporin Hypersensitivity



Beta-Lactam Allergy Summary


Drug to be Administered		History of a Penicillin Allergy/Hypersensitivity	History of Cephalosporin Allergy/Hypersensitivity	
Benign ction Io)	Penicillin Derivative	Amoxicillin drug challenge	Administer penicillin normally (no testing is needed)	
Nona-naphylactic Beni Cutaneous Reaction (>5 Years Ago) Derivative Derivative		Administer cephalosporin normally (no testing is needed)	<u>Structurally Similar</u> Cephalosporin skin testing (when available) followed by cephalosporin drug challenge <u>OR</u> Cephalosporin drug challenge only in low-risk patients	
Nona- Cut			<u>Structurally Dissimilar</u> Cephalosporin drug challenge	
Generation Mediated Mediated Mediated Mediated Mediated		Penicillin skin testing followed by amoxicillin drug challenge	Penicillin skin testing followed by amoxicillin drug challenge <u>OR</u> Cephalosporin skin testing (when available)	
Anaphylactic Read OR Recent Ig-E Meo Reaction (<5 years	Cephalosporin	<u>Structurally Similar</u> Penicillin skin testing followed by amoxicillin drug challenge and Administer cephalosporin normally	Cephalosporin skin testing (when available)	
	Derivative	<u>Structurally Dissimilar</u> Administer cephalosporin normally (no testing is needed)	followed by cephalosporin drug challenge	

Khan JACI 2022 (adapted by Deanna McDanel, PharmD)

Original Article

Cross-Reactivity to Cephalosporins and Carbapenems in Penicillin-Allergic Patients: Two Systematic Reviews and Meta-Analyses

Any carbapenem



Carbapenem Administration in Penicillin or Cephalosporin Allergy

Consensus-Based Statement	Strength of Recommendation	Certainty of Evidence
We recommend that in patients with a history of penicillin or cephalosporin allergy, a carbapenem may be administered without testing or additional precautions.	Strong	Moderate

Support for Penicillin Allergy Assessments

Don't overuse non-beta lactam antibiotics in patients with a history of penicillin allergy, without an appropriate evaluation.

While about 10 percent of the population reports a history of penicillin allergy, studies show that 90 percent on more of these patients are not allergic to penicillins and are able to take these antibiotics safely. The main reason for this observation is that penicillin allergy is often misdiagnosed and when present wanes over time in most (but not all) individuals. Patients labeled penicillin-allergic are more likely to be treated with alternative antibiotics (such as vancomycin and quinolones), have higher medical costs, experience longer hospital stays, and are more likely to develop complications such as infections with vancomycin-resistant enterococcus (VRE) and Clostridium difficile.

Evaluation for specific IgE to penicillin can be carried out by skin testing. Ideally, penicillin skin testing should be performed with both major and minor determinants. The negative predictive value of penicillin skin testing for immediate reactions approaches 100 percent, whereas the positive predictive value is between 40 and 100 percent. The usefulness of in vitro tests for penicillin-specific IgE is limited by their uncertain predictive value. They are not suitable substitutes for penicillin skin testing.

By identifying the overwhelming majority of individuals who can safely receive penicillin and penicillin-like drugs, we can improve the appropriateness of antibiotic therapy and clinical care outcomes.

In patients with a history of β -lactam allergy, we suggest that ASPs promote allergy assessments and penicillin (PCN) skin testing when appropriate

Assessing penicillin allergy: About 15% of hospitalized patients report an allergy to penicillin^[68]. However, less than 1% of the US population has a serious penicillin allergy that would preclude treatment with a beta-lactam antibiotic^{(69]}. There are several effective approaches to properly assess penicillin allergies, including history and physical examination, challenge doses, and skin testing^(60, 71). Nurses may be able to play an important role in improving penicillin allergy assessments⁽²⁷⁾.





An initiative of the ABIM Foundation

American Academy of Allergy Asthma & Immunology



NICE Is it Real


Is it Really a Penicillin Allergy?



of Allergy, Asthma & Immunology




De-labeling Considerations



Samarakoon Ann Allergy Asthma Immunol 2023

De-Labeling Challenges Ahead



Mancini Clin Infect Dis 2020; Blumenthal JACI 2017; Harada Allergy Asthma Proc 2012; Macy JACI Pract 2017; Gerace JACI Pract 2015; Rimawi J Hosp Med 2013

Barriers and Facilitators



Ngassa Ann Allergy Asthma Immunol 2024

Penicillin Allergy De-Labeling

Allergies/Contraindications

Add a new agent + Add E	ull Search				View Procedure-Allergy Interactions	🍓 View Drug-Al
	Reaction	Severity	Reaction Type	Noted	Updated	
Allergies						
Bactrim (Sulfamethoxazole-trimethoprim) Mouth sores	Other (See Comments)	Not Specified		3/9/2017	Past	Jpdates
Ceclor (Cefaclor)	Hives	Not Specified		1/20/2016	Past	Jpdates
Cephalexin		Not Specified		6/27/2015	Past	Jpdates
Doxycycline	Hives	Not Specified		1/20/2016	Past	Jpdates
Duricef (Cefadroxil)	Hives	Not Specified		1/20/2016	Past	Jpdates
Penicillins Cleared by md not allergic to cillins		Not Specified		6/27/2015	Past I	Jpdates
Zithromax (Azithromycin)	Hives	Not Specified		1/20/2016	Past	Jpdates
Amoxicillin (Bulk) Not allergic / her doc	Rash	Low		6/27/2015	Past	Jpdates

Deletion Reason: Resolution of allergy: No longer allergic to penicillin.

dd a new agent	+ Add Eull Search			View Proce	dure-Allergy Interactions
	Reaction	Severity	Reaction Type	Noted	Updated
Allergies					
Penicillins	Unknown	Not Specified	Allergy/Hypersensitivity	6/15/2010	Past Updates
Tolerated Oxacillin and A	moxicillin.				
Ampicillin	Unknown	Not Specified	Allergy/Hypersensitivity-	12/24/2009	Past Updates

Preventing Re-labeling

BestPractice Advisory -				
An amoxicillin challenge	with "no reaction" was p	reviously documented	and a Penicillin allergy	was added. Please review.
Amoxicillin oral challer	nge results? : No Rea	ction (10/12/15 1522	2)	
Allergies as of 10/12	/2015		Review	Complete On: 1/25/2015 By:
Allergen		Noted	Reaction Type	Reactions
Penicillins		10/12/2015	Topical	Atopic Dermatitis
Acknowledge reason:	True allergy Allergy will b	A e removed Will discus	ss with provider	₽ 🗅
5 Allergies				
	re applied automatically: dvisory has been sent via	in Basket		
•				<u> </u>
		Accept 8	k <u>S</u> tay <u>A</u> cc	ept <u>C</u> ancel

2018: © 2018 Epic Systems Corporation. Used with permission.

 BPA + pharmacist counseling x 2 + wallet card + chart review → "re-labeling" reduction from 12.9% to 2.5%

Lutfeali J Allergy Clin Immunol Pract 2021

Acknowledgements



Rheumatology & Allergy Clinical Epidemiology Research Center Massachusetts General Hospital

> Zachary Wallace Yuqing Zhang Hyon Choi Chio Yokose Natalie McCormick April Jorge John Accarino Naomi Patel Ana Fernandes

Guy Katz Allen Judd Emily Byrne Liam Smith Chantal Lemoine-Soto Andrew King Bohang Jiang Miao Lin Baijun Zhou







Contribute to the COVID-19 Vaccine Allergy Registry! allergyresearch.massge neral.org





